Expert Interview
A second opinion: Discussing the standard of care and potential of AstraZeneca’s Farxiga (dapagliflozin), which recently received FDA approval of label expansion to treat heart failure in a broader range of patients.
Ticker(s): AZNInstitution: Providence St. Joseph Heart Institute
- Medical director of the Center for Cardiovascular Analytics, Research, and Data Science (CARDS) at the Providence St. Joseph Heart Institute in Portland, Oregon and an adjunct faculty member of the Ciccarone Center for the Prevention of Heart Disease at the Johns Hopkins Hospital in Baltimore, Maryland.
- Currently manages 450 patients with symptomatic chronic heart failure and has prescribed Verquvo for 3-4 patients thus far.
- Currently managing 125 patients with SHTG and is comfortable discussing historical treatment approaches for severe hypertriglyceridemia (e.g., fibrates, omega 3 fatty acids), unmet needs with these therapies across different populations, the efficacy and safety of pegozafermin in the ENTRIGUE trial
- Principal clinical interests include identifying, coordinating, and implementing cardiovascular care improvement strategies.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
